勘误：靶向BMK1会损害黑色素瘤对BRAF和MEK1/2联合抑制的耐药性。
Corrigendum: Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma.
作者信息
Song Chengli, Wang Lina, Xu Qiang, Wang Kai, Xie Dan, Yu Zhe, Jiang Kui, Liao Lujian, Yates John R, Lee Jiing-Dwan, Yang Qingkai
出版信息
Sci Rep. 2017 May 26;7:46833. doi: 10.1038/srep46833.
Abstract
This corrects the article DOI: 10.1038/srep46244.
摘要
本文更正了文章的数字对象标识符
10.1038/srep46244。
相似文献
1
Corrigendum: Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma.勘误：靶向BMK1会损害黑色素瘤对BRAF和MEK1/2联合抑制的耐药性。
Sci Rep. 2017 May 26;7:46833. doi: 10.1038/srep46833.
2
Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.BRAF 突变型黑色素瘤细胞对 BRAFV600E、MEK1/2 和 PI3K/mTOR 特异性抑制剂的原发性交叉耐药性可通过双重途径阻断来对抗。
Oncotarget. 2016 Jan 26;7(4):3947-65. doi: 10.18632/oncotarget.6600.
3
Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.先前存在的 MEK1P124 突变会降低转移性黑色素瘤患者对 BRAF 抑制剂的反应。
Clin Cancer Res. 2015 Jan 1;21(1):98-105. doi: 10.1158/1078-0432.CCR-14-0759. Epub 2014 Nov 4.
4
Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.Mcl-1的过表达使黑色素瘤对BRAFV600E抑制剂单独使用以及与MEK1/2抑制剂联合使用均产生耐药性。
Oncotarget. 2015 Dec 1;6(38):40535-56. doi: 10.18632/oncotarget.5755.
5
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.转移性黑色素瘤患者对威罗菲尼耐药的药效学作用和机制。
J Clin Oncol. 2013 May 10;31(14):1767-74. doi: 10.1200/JCO.2012.44.7888. Epub 2013 Apr 8.
6
ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma.ERBB激活可调节驱动基因阴性黑色素瘤亚组对MEK1/2抑制的敏感性。
Oncotarget. 2015 Sep 8;6(26):22348-60. doi: 10.18632/oncotarget.4255.
7
The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells.MEK1/2 抑制剂 AS703026 可规避人恶性黑素瘤细胞对 BRAF 抑制剂 PLX4032 的耐药性。
Am J Med Sci. 2013 Dec;346(6):494-8. doi: 10.1097/MAJ.0b013e318298a185.
8
Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.获得性 BRAF 抑制耐药可导致对联合 BRAF/MEK 抑制的交叉耐药。
J Invest Dermatol. 2012 Jul;132(7):1850-9. doi: 10.1038/jid.2012.63. Epub 2012 Mar 22.
9
Erratum: Dehydrocorydaline Inhibits Cell Proliferation, Migration and Invasion via Suppressing MEK1/2-ERK1/2 Cascade in Melanoma [Corrigendum].勘误：脱氢紫堇碱通过抑制黑色素瘤中的MEK1/2-ERK1/2级联反应抑制细胞增殖、迁移和侵袭 [更正]。
Onco Targets Ther. 2021 Nov 23;14:5333-5334. doi: 10.2147/OTT.S350023. eCollection 2021.
10
Combination therapy of melanoma using kinase inhibitors.使用激酶抑制剂对黑色素瘤进行联合治疗。
Curr Opin Oncol. 2015 Mar;27(2):134-40. doi: 10.1097/CCO.0000000000000160.
Zotero 插件